Zynex, Inc. (ZYXI) – Press Releases
-
Zynex Sets First Quarter 2024 Earnings Call
-
Zynex Earns Prestigious 2024 Top Workplaces USA Employer Recognition Award
-
Zynex Reports Fourth Quarter and Full Year 2023 Financial Results
-
Zynex Sets Fourth Quarter and Full Year 2023 Earnings Call
-
Zynex Introduces New Products
-
Zynex Receives FDA Clearance for its Next Generation NMES Device
-
Zynex Recognized in Top 25 Medical Device Companies for 2024
-
Zynex to Participate at the Needham Annual Growth Conference
-
Zynex Ranked in Forbes List of "America's Most Successful Small-Cap Companies 2024"
-
Zynex Submits FDA Application for its Next Generation NMES Device
-
Zynex Named as a Winner in the Deloitte 2023 Technology Fast 500 Awards for the 5th Consecutive Year
-
Zynex Announces Share Repurchase Program
-
Zynex Announces Review of Strategic Alternatives
-
Zynex Reports Third Quarter 2023 Financial Results
-
Zynex Recognized in Top 100 Healthcare Technologies Companies for Second Year in a Row
-
Zynex, Inc Sets Third Quarter 2023 Earnings Call
-
Zynex to Present at the Cantor Global Healthcare Conference
-
Zynex Announces Share Repurchase Program
-
Zynex to Present at the H.C. Wainwright Global Investment Conference
-
Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600
-
Zynex Announces 1 Millionth Patient Milestone
-
Zynex, Inc Announces New Therapy Products
-
Zynex, Inc Founder and CEO Thomas Sandgaard to participate in Benzinga's Pharma Companies vs. A Tough Macro Backdrop Free Webinar on August 3rd at 12:15 PM ET
-
Zynex Reports Second Quarter 2023 Financial Results
-
Zynex, Inc. Sets Second Quarter 2023 Earnings Call
-
Zynex, Inc. (NASD: ZYXI) Wins 2023 National Top Workplaces Award in the Manufacturing Industry Category
-
Zynex Reports Preliminary Second Quarter 2023 Results
-
Zynex, Inc. Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program
-
Zynex Receives FDA Clearance of CM-1600 Monitor for Improved Blood and Fluid Management
-
Zynex Announces Share Buyback Program
-
Zynex Prices Upsized $52.5 Million Convertible Senior Notes Offering
-
Zynex Announces Update Regarding Previously Announced Offerings
-
Zynex Announces Proposed Secondary Public Offering of Common Stock
-
Zynex Announces Proposed $50 Million Offering of Convertible Senior Notes
-
Zynex Announces 2023 First Quarter Earnings
-
Zynex, Inc. to Announce First Quarter 2023 Financial Results
-
Zynex Reports Preliminary First Quarter 2023 Results
-
Bragar Eagel & Squire, P.C. Is Investigating Veradigm, LivePerson, First Republic, and Zynex and Encourages Investors to Contact the Firm
-
Zynex Earns Spot on Financial Times List of "The Americas' Fastest-Growing Companies 2023" for Second Consecutive Year
-
Zynex Included in Denver-Area's Top 10 Biotechnology/Bioscience Companies
-
Zynex Announces 2022 Fourth Quarter and Full Year Earnings
-
Zynex, Inc. Reschedules Release of Fourth Quarter and Full Year 2022 Financial Results
-
Zynex, Inc. to Postpone Fourth Quarter and Full Year 2022 Financial Results Release and Conference Call
-
Zynex, Inc. to Announce Fourth Quarter and Full Year 2022 Financial Results
-
Zynex Leases New Facility to Accommodate Growth
-
Zynex Announces Inclusion in MSCI USA Small Cap Index
-
Intrinsic’s Growing Transaction Opinions Practice Issued Two Public Company Fairness Opinions in 2022
-
Zynex Monitoring Announces Community Blood Drive and Research Collaboration Trial for its Fluid Monitoring System
-
Zynex Recognized in The Power 500 Healthcare Technology Companies
-
Zynex Reports Preliminary Fourth Quarter 2022 Results
Back to ZYXI Stock Lookup
